2024
Understanding the impact of night-to-night sleep variations on glucose regulation in healthy young adults: Insights from Ng et al. (2024)
Ding Q, Wojeck B, Zinchuk A. Understanding the impact of night-to-night sleep variations on glucose regulation in healthy young adults: Insights from Ng et al. (2024). Sleep 2024, zsae253. PMID: 39460669, DOI: 10.1093/sleep/zsae253.Peer-Reviewed Original ResearchEffect of obesity on sleep apnea pathogenesis differs in women versus men: multiple mediation analyses in the retrospective SNOOzzzE cohort
Nokes B, Orr J, White S, Luu S, Chen Z, Alex R, Sands S, Wojeck B, Owens R, Malhotra A, Schmickl C. Effect of obesity on sleep apnea pathogenesis differs in women versus men: multiple mediation analyses in the retrospective SNOOzzzE cohort. Journal Of Applied Physiology 2024, 136: 1516-1525. PMID: 38660729, PMCID: PMC11368527, DOI: 10.1152/japplphysiol.00925.2023.Peer-Reviewed Original ResearchApnea-hypopnea indexObstructive sleep apneaBody mass indexEffect of body mass indexCirculatory delayArousal thresholdAssociated with apnea-hypopnea indexObstructive sleep apnea risk factorsObstructive Sleep Apnea EndotypesIn-laboratory polysomnographyUpper airway collapseEvents per hourHigh arousal thresholdsEffect of obesityHypopnea indexOSA pathogenesisSleep apneaConsecutive adultsSleep clinicEndotypic traitsAirway collapseMass indexPathogenesis differencesRisk factorsPolysomnography signalsChapter 35 Diseases of the pituitary gland
Wojeck B, Kryger M. Chapter 35 Diseases of the pituitary gland. 2024, 374-378.e1. DOI: 10.1016/b978-0-323-65403-6.00044-5.Chapters
2023
Role of metformin in the management of type 2 diabetes: recent advances.
Gonzalez-Lopez C, Wojeck B. Role of metformin in the management of type 2 diabetes: recent advances. Polish Archives Of Internal Medicine 2023, 133 PMID: 37317976, DOI: 10.20452/pamw.16511.Peer-Reviewed Original ResearchConceptsType 2 diabetesAntidiabetic medicationsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsCardio-renal protectionCotransporter 2 inhibitorsFirst-line agentsFirst-line therapyPolycystic ovary syndromeRole of metforminRisk of hypoglycemiaTreatment of obesityManagement of diabetesBlood glucose levelsMechanism of actionInitial therapyWay diabetesGestational diabetesOvary syndromeHeart failureRenal diseaseInsulin resistanceInsulin sensitivityReceptor agonistPolysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study.
Wojeck B, Inzucchi S, Qin L, Yaggi H. Polysomnographic predictors of incident diabetes and pre-diabetes: an analysis of the DREAM study. Journal Of Clinical Sleep Medicine 2023, 19: 703-710. PMID: 36689314, PMCID: PMC10071389, DOI: 10.5664/jcsm.10414.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexBody mass indexIncident diabetesPolysomnographic predictorsMass indexOxygen saturationMean nocturnal oxygen saturationObstructive sleep apnea (OSA) evaluationObstructive sleep apnea populationEpworth Sleepiness Scale scoreSleep apnea populationGlucose-lowering medicationsNocturnal oxygen saturationSleep-disordered breathingIncidence of diabetesPeriodic limb movementsLaboratory-based polysomnographyCheyne-Stokes respirationSleep apnea severitySleep apnea evaluationIncident prediabetesOxygen desaturationCentral apneaHemoglobin A1cPrimary outcome
2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing 2022, 27: 669-672. PMID: 35596030, PMCID: PMC10212814, DOI: 10.1007/s11325-022-02594-2.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaIncident obstructive sleep apneaAtherosclerotic CV diseaseVERTIS CVSleep apneaMultivariable Cox proportional hazards regression modelsIncidence of OSACox proportional hazards regression modelBaseline obstructive sleep apneaMajor adverse CV eventsProportional hazards regression modelsCV outcome trialsEffect of ertugliflozinInvestigator-reported eventsVERTIS-CV trialAdverse CV eventsSleep apnea syndromeRelative risk reductionHazards regression modelsType 2 diabetesCV eventsCV diseasePrimary endpointInhibitor empagliflozinOutcome trials
2021
Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study.
Ding Q, Qin L, Wojeck B, Inzucchi SE, Ibrahim A, Bravata DM, Strohl KP, Yaggi HK, Zinchuk AV. Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes: Results from the DREAM Study. Annals Of The American Thoracic Society 2021, 18: 2067-2078. PMID: 34185617, PMCID: PMC8641817, DOI: 10.1513/annalsats.202012-1556oc.Peer-Reviewed Original ResearchConceptsApnea-hypopnea indexObstructive sleep apneaPolysomnographic phenotypeIncident T2DMRisk of T2DMPredictive valueSleep apneaBlood glucoseRisk factorsCardiovascular diseaseMild obstructive sleep apneaIncident type 2 diabetesMultivariable-adjusted regression modelsCox proportional hazards regressionNew physician diagnosisT2DM risk predictionIncident cardiovascular diseaseIncident type 2Body mass indexProportional hazards regressionT2DM risk factorsBehavioral risk factorsType 2 diabetesMale veteran populationRisk regression modelsLessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors.
Wojeck BS, Inzucchi SE. Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. Diabetes Spectrum 2021, 34: 235-242. PMID: 34511849, PMCID: PMC8387615, DOI: 10.2337/ds20-0070.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSodium-glucose cotransporter 2 inhibitorsCotransporter 2 inhibitorsMajor clinical outcome trialsRecent large clinical trialsDiabetes treatment guidelinesGlucose-lowering medicationsChronic kidney diseaseClinical outcome trialsLarge clinical trialsRenal outcomesOutcome trialsTreatment guidelinesKidney diseaseRisk factorsClinical trialsMedicationsTrialsInhibitorsDiabetesDiseaseResponse to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015
Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE. Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007–3015. Diabetes Care 2021, 44: e137-e138. PMID: 34016610, PMCID: PMC8247494, DOI: 10.2337/dci21-0009.Commentaries, Editorials and LettersAssociations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes
Ding Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes. 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.Peer-Reviewed Original Research
2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatientsThe Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaRenal outcomesOSA statusSleep apneaNew-onset obstructive sleep apneaMultivariable-adjusted Cox regression modelsBaseline obstructive sleep apneaMajor adverse CV eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEImpact of empagliflozinPlacebo-adjusted reductionsAdverse CV eventsEffect of empagliflozinHeart failure hospitalizationSystolic blood pressureCox regression modelStandard of careCV deathCV eventsCV outcomesEmpagliflozin treatmentEMPA-REGRenal eventsCV disease